BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 18559569)

  • 1. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
    Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling.
    Aspinwall LG; Leaf SL; Kohlmann W; Dola ER; Leachman SA
    J Am Acad Dermatol; 2009 May; 60(5):745-57. PubMed ID: 19278751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic carcinoma surveillance in patients with familial melanoma.
    Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
    Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome.
    Aspinwall LG; Taber JM; Leaf SL; Kohlmann W; Leachman SA
    Psychooncology; 2013 Feb; 22(2):276-89. PubMed ID: 23382133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic testing in familial melanoma: uptake and implications.
    de Snoo FA; Riedijk SR; van Mil AM; Bergman W; ter Huurne JA; Timman R; Bertina W; Gruis NA; Vasen HF; van Haeringen A; Breuning MH; Tibben A
    Psychooncology; 2008 Aug; 17(8):790-6. PubMed ID: 18613292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
    Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the CDKN2A locus in patients with multiple primary melanomas.
    Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
    J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone.
    Taber JM; Aspinwall LG; Stump TK; Kohlmann W; Champine M; Leachman SA
    J Behav Med; 2015 Oct; 38(5):740-53. PubMed ID: 26178773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Family members' perceptions of genetic testing for malignant melanoma--a prospective interview study.
    Bergenmar M; Hansson J; Brandberg Y
    Eur J Oncol Nurs; 2009 Apr; 13(2):74-80. PubMed ID: 19179113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
    Goldstein AM; Landi MT; Tsang S; Fraser MC; Munroe DJ; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2208-12. PubMed ID: 16172233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
    Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
    Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
    Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
    Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.